Atlas Trials

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Clinical trial NCT03942224 · UNKNOWN

Trial details

NCT number
NCT03942224
Sponsor
Emory University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Plasma Cell Myeloma
Start date
2019-07-03
Primary completion
2025-07-31
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.